Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Tumor-Immune Cell Communications via Enantioselectively Targeting SLC G-Quadruplexes.

Journal of the American Chemical Society·2026
Same author

EpiGIS pro: an AI-powered geospatial intelligence platform for integrated disease surveillance and predictive analytics.

International journal of health geographics·2026
Same author

Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study.

Veterinary microbiology·2026
Same author

White matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.

Brain : a journal of neurology·2026
Same author

Short- and long-term outcome and quality of life assessment in dogs undergoing transvenous coil embolization of congenital intrahepatic portosystemic shunts.

Veterinary surgery : VS·2026
Same author

Step cadence to guide physical activity intensity in coronary heart disease.

Frontiers in sports and active living·2026

Related Experiment Video

Updated: Feb 24, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.4K

Anticancer metallohelices: nanomolar potency and high selectivity.

Rebecca A Kaner1,2, Simon J Allison3, Alan D Faulkner1

  • 1Department of Chemistry , University of Warwick , Coventry , CV4 7AL , UK .

Chemical Science
|August 16, 2017
PubMed
Summary

New iron helicate complexes show potent and selective anticancer activity, particularly in cancer cells lacking p53. These compounds exhibit low general toxicity, offering a promising alternative cancer therapy.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

59.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.4K
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

59.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Area of Science:

  • Coordination Chemistry
  • Supramolecular Chemistry
  • Medicinal Chemistry

Background:

  • Helicate-like architectures offer unique structural motifs for developing novel therapeutic agents.
  • Iron complexes are increasingly explored for their potential in cancer treatment due to their redox properties and biocompatibility.

Purpose of the Study:

  • To synthesize and characterize novel helicate-like iron complexes.
  • To evaluate the in vitro anticancer activity and selectivity of these complexes.
  • To investigate the mechanism of action and general toxicity profile.

Main Methods:

  • Diastereoselective self-assembly of iron(II) with bidentate ditopic ligands (NN-NN).
  • In vitro cytotoxicity assays against various cancer cell lines and healthy cells.
  • Structure-activity relationship analysis.
  • General toxicity assessments including antimicrobial and in vivo studies.
  • Mechanism of action studies, including DNA interaction and apoptosis induction.

Main Results:

  • Six pairs of enantiomeric [Fe2L3]Cl4 complexes were successfully synthesized with good water solubility and stability.
  • The complexes demonstrated potent and structure-dependent anticancer activity with IC50 values as low as 40 nM.
  • Preferential activity was observed against cancer cells lacking functional p53.
  • Exceptional selectivity was noted, with IC50 values nearly three orders of magnitude higher for healthy cells compared to cisplatin.
  • Low general toxicity was observed across antimicrobial, amoebal, and insect models, with no adverse effects in Manduca sexta larvae.

Conclusions:

  • Novel helicate-like iron complexes represent a promising class of anticancer agents with high potency and selectivity.
  • The observed preferential activity against p53-deficient cancer cells warrants further investigation for targeted cancer therapy.
  • The favorable toxicity profile suggests potential for reduced side effects compared to conventional chemotherapeutics.